Q3 Earnings Forecast for Brainsway Issued By HC Wainwright

Key Points

• HC Wainwright has raised its Q3 2025 earnings estimate for Brainsway to $0.12 per share, up from the previous estimate of $0.10, and maintains a "Buy" rating with a price target of $17.00.
• Despite a recent downgrade to a "hold" rating by Wall Street Zen, Northland Securities increased their target price for Brainsway from $15.00 to $19.00, indicating varying opinions among analysts.
• Brainsway reported Q2 earnings of $0.10 EPS, surpassing expectations, and has seen growing interest from institutional investors, with around 30.11% of the stock now held by them.

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY - Free Report) - Research analysts at HC Wainwright lifted their Q3 2025 EPS estimates for shares of Brainsway in a note issued to investors on Thursday, August 14th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn $0.12 per share for the quarter, up from their previous forecast of $0.10. HC Wainwright has a "Buy" rating and a $17.00 price objective on the stock. The consensus estimate for Brainsway's current full-year earnings is $0.08 per share. HC Wainwright also issued estimates for Brainsway's FY2025 earnings at $0.40 EPS, Q1 2026 earnings at $0.10 EPS, Q3 2026 earnings at $0.18 EPS, Q4 2026 earnings at $0.24 EPS and FY2026 earnings at $0.64 EPS.

A number of other research analysts have also recently issued reports on BWAY. Wall Street Zen raised shares of Brainsway from a "hold" rating to a "buy" rating in a research report on Sunday. Northland Securities raised their price objective on shares of Brainsway from $15.00 to $19.00 and gave the company an "outperform" rating in a research note on Thursday, August 14th. Two equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average price target of $18.00.

Brainsway Stock Up 0.7%

Shares of NASDAQ:BWAY traded up $0.10 on Friday, hitting $14.57. The company had a trading volume of 36,786 shares, compared to its average volume of 53,876. The firm's 50-day simple moving average is $12.21 and its two-hundred day simple moving average is $10.59. Brainsway has a 1 year low of $7.06 and a 1 year high of $15.00. The firm has a market capitalization of $275.37 million, a price-to-earnings ratio of 56.04 and a beta of 1.42.

Brainsway (NASDAQ:BWAY - Get Free Report) last posted its earnings results on Wednesday, August 13th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.07 by $0.03. Brainsway had a net margin of 11.60% and a return on equity of 8.97%. The firm had revenue of $12.63 million during the quarter, compared to analysts' expectations of $12.34 million. Brainsway has set its FY 2025 guidance at EPS.

Institutional Trading of Brainsway

A number of large investors have recently made changes to their positions in BWAY. Valor Management LLC bought a new stake in shares of Brainsway in the fourth quarter worth approximately $19,838,000. Eagle Global Advisors LLC bought a new stake in shares of Brainsway in the first quarter worth approximately $590,000. MYDA Advisors LLC grew its stake in shares of Brainsway by 100.2% in the fourth quarter. MYDA Advisors LLC now owns 120,100 shares of the company's stock worth $1,133,000 after acquiring an additional 60,100 shares during the period. Two Sigma Advisers LP boosted its holdings in shares of Brainsway by 32.6% in the fourth quarter. Two Sigma Advisers LP now owns 60,600 shares of the company's stock worth $571,000 after buying an additional 14,900 shares during the last quarter. Finally, Trexquant Investment LP purchased a new position in shares of Brainsway in the first quarter worth approximately $129,000. 30.11% of the stock is currently owned by institutional investors.

Brainsway Company Profile

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.